Victoria Johnson

A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.

3-month topline data showed a 72% reduction in pain and a 109% improvement in function versus placebo, both exceeding prespecified FDA thresholds for Phase III advancement.

Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.

Findings from an independent, blinded re-adjudication of ADVOCATE's primary endpoints will be presented at an FDA hearing scheduled for July 2026.

Key changes in the 2026 ACR/SAA/SPARTAN guideline update elevate JAK inhibitors to a strong recommendation and introduce nociplastic pain guidance.

Iain McInnes, MD, PhD, discussed comparing bimekizumab and risankizumab for PsA.

Laura Coates, MBChB, PhD, discusses data showing early separation in ACR50 and disease activity measures at week 4, before substantial weight loss.

Check out what coverage RheumLive has slated for the upcoming congress in London.

Guselkumab (Tremfya) was originally approved in 2020, with its indication expanded to pediatric patients with psoriatic arthritis in 2025.

New JIA guidance urges early biologics, favors oral methotrexate, adds mental health screening, and reshapes tapering and monitoring.

Phase 2/3 China trial shows IL‑17A antibody vunakizumab rapidly improves radiographic axSpA symptoms vs placebo, with benefits lasting to 32 weeks.

The new approval is backed by ADAPT SERON results showing significant MG-ADL improvement and consistent safety.

April is Sjögren's Awareness Month and we took a look at how the field's fast-growing pipeline is reshaping care.

FDA reviews Gazyva for systemic lupus after ALLEGORY shows stronger responses, fewer flares and steroid use—potential first anti‑CD20 option for SLE.

Experts discuss CTD-ILD guidance and nerandomilast reshape screening, progression monitoring, and multidisciplinary treatment.

Real-world data suggest IL-23 biologics may cut 3-year psoriatic arthritis risk in psoriasis versus TNF and IL-17 therapies.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE.

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

Take a look back at 5 RheumLive exclusive conversations ranging from PsA to giant cell arteritis from RWCS 2026 in Maui, Hawaii.

Full data from BE BOLD supporting bimekizumab over risankizumab are expected at a future medical meeting.

The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

This preview of RWCS 2026 highlights some of the sessions and interviews to look forward to.

This rheumatology month in review emphasizes new data and FDA actions.

Arthur Mandelin, MD, PhD, and Daniel White, MS, ScD, share what they consider the largest current unmet need in the RA field.

A recent study reveals that treating gout effectively lowers cardiovascular risks, highlighting the importance of personalized urate-lowering therapy.

A recent trial reveals that transcutaneous auricular vagus nerve stimulation does not significantly reduce pain in erosive hand osteoarthritis compared to placebo.